VTYX News and Press, Ventyx Biosciences Inc. From 01/08/26

Halper Sadeh LLC Encourages HOLX, VTYX, QRVO, TEX Shareholders to Contact the Firm to Discuss Their Rights PR Newswire Shareholders should contact the firm as there may be limited time to enforce your rights. NEW YORK , Jan. 8, 2026 /PRNewswire/ -- Halper Sadeh LLC, an ...

Shareholders should contact the firm as there may be limited time to enforce your rights Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Ventyx Biosciences, Inc. (NASDAQ: VTYX) to Eli Lilly and Company for $14.00 per share is fair to Ventyx shareh...

2026-01-08 07:15:10 ET Oppenheimer analyst issues PERFORM recommendation for VTYX on January 8, 2026 12:01PM ET. The previous analyst recommendation was Outperform. VTYX was trading at $13.73 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2026-01-07 17:20:56 ET More on Ventyx Biosciences, Eli Lilly Eli Lilly's 2026 Resolution: Volume Is The New Price Eli Lilly's Trifecta: Fundamentals, Undervaluation, And Momentum I Expect Novo Nordisk To Outperform Eli Lilly In 2026: Here's Why Lilly to work ...

Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases PR Newswire Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation Acquisition builds on Lilly's est...

2026-01-07 09:52:50 ET More on Ventyx Biosciences, Eli Lilly Eli Lilly's 2026 Resolution: Volume Is The New Price Eli Lilly's Trifecta: Fundamentals, Undervaluation, And Momentum I Expect Novo Nordisk To Outperform Eli Lilly In 2026: Here's Why Biggest stock ...

2026-01-07 05:01:16 ET More on related stocks: Mobileye Global Inc. (MBLY) Presents at UBS Global Industrials and Transportation Conference Transcript Mobileye: ADAS Thrives While Advanced Products Stuck In Neutral, Still Undervalued HIVE Digital: 'Cheap' Despite Exp...

2026-01-06 15:58:35 ET More on Ventyx Biosciences, Eli Lilly Eli Lilly's Trifecta: Fundamentals, Undervaluation, And Momentum I Expect Novo Nordisk To Outperform Eli Lilly In 2026: Here's Why Eli Lilly: Mr. Market Finally Woke Up, But I'm Not Out Yet (Rating Downgrad...

Strengthening our Advisory Board with addition of Mark McKenna as Strategic Advisor and Peter Libby, MD as a Clinical Advisor Expanding the Phase 2 recurrent pericarditis study into Canada, EU and the UK to evaluate QD dose ranging in preparation for the global Phase 3 development pla...

2025-12-01 14:34:09 ET More on Neumora Therapeutics Neumora Therapeutics, Inc. (NMRA) Discusses NMRA-215 Preclinical Results and Portfolio Updates, Including Obesity and Alzheimer's Disease Programs - Slideshow Neumora Therapeutics, Inc. (NMRA) Discusses NMRA-215 Preclinical...